Aethon
www.aethon.com
 
Aethon is the leading maker of practical, dependable courier robots for hospitals. They offer a powerful product platform with multiple applications. From tracking and recovering goods, to finding and delivering goods, they manage hospital assets from every angle. Their products work in conjunction with each other, or separately, depending on the hospitals specialized needs. Their team consists of hospital environment experts with over 100 years combined robotic experience in healthcare, so they understand the people and processes involved in running a hospital. They've used that knowledge to develop an automated technology platform that helps increase productivity and staff satisfaction, while saving hospitals time and money.

Biodel, Inc.
www.biodel.com
 
Biodel Inc. is a biopharmaceutical drug delivery company. Biodel develops drug delivery technologies that increase drug efficacy, enhance drug performance, and make drugs easier for patients to take. This technology is applicable to a wide range of peptides, proteins and other macromolecules. Using this technology, Biodel has developed a novel drug formulation of recombinant human insulin designed to speed the delivery of insulin into the blood called Viaject^TM to treat patients with Type 1 and Type 2 diabetes. On May 17, 2007, Biodel had its initial public offering and now trades on Nasdaq under the symbol “BIOD."

Cequent Pharmaceuticals, Inc.
www.cequentpharma.com
 
Cequent has a powerful and extensible technology platform for treating GI disorders. Furthermore, the company, with its unique solution to both manufacturing and delivery, is an attractive acquisition target for the many publicly-traded RNAi companies, such as Alnylam and Sirna. Cequent was founded to commercialize the discoveries of Dr. Chiange Li while at Harvard-BIDMC. The company is developing a novel therapeutic probiotic which delivers inhibitory RNA directly to the gut for the treatment of a variety of gastrointestinal disorders such as irritable bowel disease, Crohn’s disease, familial polyposis (pre-colon cancer) and colon cancer. The technology elegantly addresses the extant challenges associated with RNAi- delivery and manufacturing. More specifically, the technology exploits the ability of certain bacteria to both penetrate into diseased tissue and, once there, produce and deploy therapeutically functional RNAi in situ. The first indication to be pursued is familial polyposis (FP), a genetic disease that leads to scores of precancerous polyps in the large intestine. Currently, FP is largely untreatable and nearly 100% of patients progress to metastatic colon cancer. Cequent is the first company to generate in vivo data showing the utility of genetically modified, probiotic bacteria producing RNAi to ameliorate the disease. This data was published in the scientific journal Nature Biotechnology. Cequent recently signed a major equity investment and collaboration agreement with Novartis.

Cutanea Life Sciences, Inc.
www.cutanealife.com
 
Cutanea Life Sciences is a development stage specialty pharmaceutical company whose mission is to strategically in-license novel, mid-stage candidates to treat diseased and aging skin conditions, aggressively advance their development and maximize intellectual property and therapeutic applications, in order to create market-leading products for out-license or commercialization. Cutanea currently has in-licensed three novel product candidates: a rosacea drug currently in Phase II clinical development, a dermal filler with a planned CE mark approval in 2008 and a topical antiviral with clinical trials initiating in late 2007 or early 2008.

EffRx, Inc.
www.effrx.com
 
EffRx has an exclusive world-wide license from Merck & Co to an effervescent form of FOSAMAX, Merck's $1 billion+ osteoporosis drug. Many patients cannot take Merck's form of FOSAMAX and hence EffRx's more tolerable version can command a significant market share. EffRx has developed and patented an improved effervescent technology that covers most pharmaceutical compounds of commercial significance. EffRx also has a special relationship with a Swiss manufacturer of effervescent drugs that will supply its needs for the foreseeable future. It has already formulated the product for clinical trials in the US and Europe that it anticipates launching during the next 12 months.

Energetiq Technology, Inc.
www.energetiq.com
 
Energetiq was founded in March, 2004 with a mission to be the preeminent developer and manufacturer of short wavelength light sources for use in the analysis and fabrication of nano-scale structures and products. Energetiq's goal is to leverage its substantial expertise to develop novel, cost effective, short wavelength light sources that will enable the production of next generation devices to be used in lithography, metrology, inspection, thin-film processing and Soft X-Ray Microscopy and a variety of applications where synchrotron radiation has traditionally been used in biological imaging markets.

EyeGate Pharmaceuticals, Inc.
www.eyegatepharma.com
 
EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate® II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. We believe the EyeGate® II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease. Eyegate is a platform technology based on electro-transport that focuses on the development of innovative devices to treat intraocular diseases of the eye such as age related macular degeneration, diabetic retinopathy, chronic macular edema, and posterior uveitis. Several drugs have been tested over the years in pre-clinical studies and can be delivered by this technology: anesthesics, steroids, NSAIDs, anticancers, antibiotics, antivirals, antifungals and various oligonucleotide constructs including RNAi. Eyegate non-invasively delivers a constant amount of drug to the posterior chamber of the eye, particularly the choroid and the retina. The device is biocompatible, safe and well tolerated.

Magellan Biosciences, Inc.
www.magellanbio.com
 
Magellan serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for near-patient testing. Scientists use the Company's discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness — from disease pathology to biomarker identification. Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TekCel.

mtm Laboratories, AG
www.mtm-laboratories.com
 
mtm laboratories is a certified developer and manufacturer of In-vitro Diagnostics for screening and diagnosis of cervical cancer with products marketed world-wide. mtm's products target the largest existing screening market in oncology. The biomarker-based diagnostic assays promise to be more cost-effective and to offer superior sensitivity and specificity compared to conventional screening methods for identifying cervical pre-cancerous and cancerous lesions.

MyoScience, Inc.
 
MyoScience, Inc. has a patented approach to treating wrinkles using safe, non-toxin-based cryo-energy to induce damage directly in the muscles of the face, thereby decreasing contractility of the fibers and reducing the overlying wrinkles. Unlike botox, which “deadens” the nerves in the face that control the muscles, MyoScience’s technology has largely the same effect and duration, but without the frozen, “death mask” appearance of botox. The MyoScience device uses multiple needles that insert into the muscles and then the needles are momentarily “frozen’ using the adiabatic expansion of nitrous oxide, resulting in the decreased contractility of the muscle fibers. Currently, Allergan’s Botox is the market leader, selling over $600 million of botox world wide for both aesthetic and therapeutic applications. Although botox has been proven to be fairly safe, its penetration is only approximately 2% of the available market due to market resistance to having a dangerous, potentially fatal drug injected into the face.

Neurotech, Inc.
www.neurotechusa.com (OTC BB: MSO.OB)
 
Neurotech is dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Neurotech's lead product (NT-501) is in clinical development for the treatment of retinal degeneration, including retinitis pigmentosa, an inherited disease leading to blindness, and the dry form of age related macular degeneration. Neurotech is also evaluating other factors that can be used with its proprietary delivery technology, Encapsulated Cell Technology, to treat additional retinal diseases.

Patholase
www.patholase.com
 
Patholase (formerly UvaCide) has developed a technology involving the use of lasers to generate light with specific frequency ranges to destroy certain pathogens without harming adjacent healthy tissue. The initial market is toenail fungus where there is a large unsatisfied demand, with over 35 million individuals in the US alone suffering from this fungal disorder and, in some severe cases, this can lead to amputation. The current pharmaceutical alternative, Lamisil, is only effective on certain patients and has some undesirable side effects.

Presidio Pharmaceuticals, Inc.
www.presidiopharma.com
 
Presidio Pharmaceuticals, Inc. is building a sustainable specialty pharmaceutical company focused on development and commercialization of novel small molecule antiviral therapeutics. It has three programs ongoing, with the latest expected to complete its first human clinical trial, in HIV, by Q-1 2008. Its lead compound is a nucleoside reverse transcriptase inhibitor (NRTI) with a novel "penultimate chain termination" mechanism. This compound shows preclinical efficacy against HIV, cytomegalovirus (CMV), and hepatitis B virus (HBV). Presidio is also developing small molecules for HIV and influenza based on its proprietary Nuclear Exclusion Technology (NEXT™) platform. This is a novel viral targeting mechanism that inhibits the importation of viral RNA and DNA into the nucleus of the cell, impeding a critical step in virus replication. In addition, the company has licensed a program from Stanford University to develop small-molecule compounds against two novel targets for HCV.